Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695471 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03695471: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03695471 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695471, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-04 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695471
The ClinicalTrials.gov registry entry for NCT03695471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03695471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695471 about?
NCT03695471 is a clinical study titled "Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides". This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread...
What is the current status of trial NCT03695471?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-02-04. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT03695471?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03695471?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.